**Specifications table**TableSubject areaBiologyMore specific subject areaMicrobiologyType of dataTablesHow data was acquiredLiterature search for mutation frequencies and genetic variants related to bedaquiline, clofazimine and linezolid resistanceData formatFilteredExperimental factorsPublished articles regarding bedaquiline, clofazimine and linezolid resistant isolates and associated mutationsExperimental featuresPreviously published mutations in *rv0678*, *rv1979c*, *rv2535c*, *atpE*, *rplC* and *rrl* genes and mutation frequencies associated with either bedaquiline-, clofazimine- or linezolid-resistant *M. tuberculosis*Data source locationSouth AfricaData accessibilityData is included in this article and accessible in related referenced articlesRelated research articleIsmail, N., Omar, S.V., Ismail, N.A., Peters, R.P.H. (2018). in vitro approaches for generation of *Mycobacterium tuberculosis* mutants resistant to bedaquiline, clofazimine or linezolid and identification of associated genetic variants, JMM (In press)

**Value of the data**•The data pertaining to genetic variants for bedaquiline, clofazimine and linezolid resistance are vital for understanding drug mechanisms of action.•A catalog such as this may prevent data replication and serve as a comparator or reference for other studies related to resistance-associated mutation.•The combined data of the resistance-associated variants could provide a starting point for the design of molecular susceptibility tests.

1. Data {#s0005}
=======

The data in this article includes previously published mutations identified in both in vitro ([Tables 1](#t0005){ref-type="table"} and [3](#t0015){ref-type="table"}) as well as clinical isolates ([Tables 2](#t0010){ref-type="table"} and [4](#t0020){ref-type="table"}) associated with bedaquiline, clofazimine or linezolid resistance. Data were filtered according to the type of mutation identified and the gene in which the mutation occurred. Where available the in vitro approach used to generate the mutant, any information around the strain the mutants were derived from, the mutant MIC value as well as the article from which the data was derived from were included in the data. As bedaquiline- and clofazimine-resistant isolates tend to harbor *rv0678* mutations, data for these mutants were presented together. The final data table ([Table 5](#t0025){ref-type="table"}) describes previously published mutation frequencies. A diversity of mutations were identified in the *rv0678* gene and were scattered along the gene. For the *atpE* gene, hotspots have been identified at positions 28 and 63. Mutations in the *rplC* and *rrl* target genes appear to be associated with either high or low-level linezolid resistance respectively. Four mutations in *rv2535c* were identified in in vivo bedaquiline and clofazimine resistant isolates. *Rv1979c* mutations were found in clinical pre-XDR and XDR isolates.Table 1Catalog of previously published mutations from bedaquiline- and clofazimine-resistant in vitro and in vivo isolates.Table 1MutationApproachNotesMIC (µg/mL)Refs.*rv0678atpErv2535c*BDQCFZ--G187C--Serial PassageFully susceptible strain\>8--[@bib1]T461CA83GIsoniazid-resistant strain\>8201_206delA83CKanamycin-resistant strain\>8--G183TPyrazinamide-resistant strain\>8A83GA63TA83GRifampicin-resistant strain\>8G74A--Fully susceptible strain--4T131CIsoniazid-resistant strain\>4T407CKanamycin-resistant strain4C204APyrazinamide-resistant strain\>4T131CRifampicin-resistant strain4--A83T--SpontaneousFully susceptible strain\>8--C403GPyrazinamide-resistant strain4--A83GPyrazinamide-resistant strain8--G187CPyrazinamide-resistant strain\>8193delG--Fully susceptible strain--2193delGFully susceptible strain4A65TFully susceptible strain4T407CPyrazinamide-resistant strain1C214TPyrazinamide-resistant strain2G137APyrazinamide-resistant strain4A97G----CinArg271in vivoMice treated with BDQ only0.120.5-1[@bib2]+CinAla14Mice treated with BDQ and CFZ0.12+CinAla140.12L44P0.12A413GWT--in vitro mutantsMutants derived from H37Rv0.25--[@bib3], [@bib5]G281AWT0.5A202GWTMutants derived from MDR *M. tuberculosis* clinical strain0.5Ins G 192-193I66M4IS6110 nt 272WT1Ins A 38--39WT1--A95T--Mutagenesis*M. smegmatis*----[@bib4], [@bib5]--C198G--Spontaneous*M. tuberculosis*----[@bib6]G187C------G183T--Spontaneous2 isolates from MDR strain0.24--0.48--[@bib7]G187C3 isolates from MDR strain0.9--3.84A83T1 isolate from MDR strain0.48C198G1 isolate from MDR strain0.48A83G1 isolate from WT strain0.3G183T3 isolates from WT strain0.48--0.96G187C4 isolates from WT strain0.24--0.9--G187C--Spontaneous--4--8x MIC--[@bib8]A95T4--8x MICC189A----Spontaneous--0.51.25[@bib9]C400T0.51.25G193 deletion----Spontaneous23 isolates--All ≤1[@bib10]G193 insertion21 isolatesC466T11 isolatesC364 insertion5 isolatesA202G5 isolatesT2C2 isolatesG58T1 isolateC107T1 isolateG125A1 isolateT29 insertion1 isolateC98A1 isolateT128G1 isolateG137A2 isolateA152G1 isolateC158T1 isolateC176T1 isolateG188A1 isolateG194A2 isolatesG197T1 isolateC226T1 isolateC251A1 isolateG266T1 isolateG269C1 isolateA292 deletion1 isolateG304A1 isolateC305T2 isolatesT341C1 isolateT365C1 isolateCGCTGGGC371--378 deletion1 isolateCG444--445 deletion1 isolateG193 insertion1 isolate--3 isolates--G265T1 isolate--A63P----Mutants from H37Rv reference strain4--[@bib11]D28GMutants from *M. tuberculosis* clinical isolates0.5E61D0.5L59V0.25I66M1[^1]Table 2Catalog of previously published mutations from bedaquiline- and clofazimine-resistant clinical isolates.Table 2**MutationNotesMIC (µg/ml)Refs.*****rv0678****atpE****rv1979c*****BDQCFZ**T124C----Clinical strains from BDQ trial0.25[@bib3]A97C0.5--C107T0.5Del C 2120.5Ins IS6110 nt 2720.5Ins C 141--1420.252T\>CWT--fMet1Ala-relapse isolate after0.54[@bib12], [@bib13], [@bib14]BDQ compassionate useT437CWTWTXDR0.781.2[@bib15]G5TWTWTPre-XDR0.734C158TWTWTPre-XDR0.392.09T350GWTWTXDR1.544.16WTWTA155CPre-XDR0.081.2Del gg 18--19----MDR isolates0.5--[@bib16]Ins G1400.25M139T0.25198--199 Ins G----Mix: WT + *rv0678* mutant0.24;0.48;1--[@bib17], [@bib18]274--275 Ins A1C148T, A187Gintergenic mutation, *rv0678* mutant0.48G334C, (-13) Ins IS61100.48C185T0.48C155T0.48C176T0.48224--225 Ins A0.24T(-44)C0.24A263GMix: WT + *rv0678* mutant0.12T116C0.12T124CMix: WT + *rv0678* mutant (silent mutation)0.12C45T0.12G256A0.12\[Ins139g\]WT--0.12--0.25--[@bib19]L142RWTBaseline and post-treatment BDQ isolates from BDQ clinical trials0.25L142RA63V0.25--1\[Del198G\] \[Del212C\] \[G233C, G78A\]WT0.12\[G66W\] \[Del198G\] \[Ins263A\] \[Del435T\]WT0.12\[Del198G\] \[Ins466C\]WT0.25\[Del435T\]WT0.25\[E113K\] \[Del198G\] \[Del435T\]WT0.25\[Del435T\]WT0.25G121EWT0.25\[L40S\] \[Del291C\] \[Ins386C\]WT0.25Del291CWT0.25\[S53P\] \[Del198G\] \[Del336C\]WT0.25M23LWT0.06M23L Ins142CWT0.12M23L \[Ins142C\] \[Ins419G\]WT0.12M23L Ins419gWT0.12\[Del19G\] \[E49stop\] \[Del198G\] \[Ins468GA\]WT0.12-\[V85A\] \[R135W\]WT0.12V85AWT0.12Ins44AWT0.06\[Ins144C\]WT0.12--0.25Ins421GWT0.12--0.25Del32GWT0.06; 0.25\[Y26stop\] \[L122P\]WT0.12L122PWT0.12\[Del214C\] \[Del198G\]WT0.06\[F79S\] \[Ins137G\]WT0.12\[Del19G\] \[Del198G\]WT0.12A98VWT0.12--0.25WTD28N0.12\[Ins139G\] + \[Ins318CG\]WT0.12\[Del274--283\] \[Ins139TG\]WT0.12\[C46R\] \[Ins139TG\] \[L40S\]WT0.12Ser53ProWT--2 XDR isolates0.52--4[@bib20]Ser53Leu1 XDR isolate0.252Tyr157Asp1 XDR isolate0.1252WT1 XDR isolate0.52WTWTG1226A3 XDR isolates: Culture negative at 6 months0.25--1 (MGIT) 0.06--0.125 (BMD)0.5 (MGIT)[@bib21]136_137insGG1226AXDR: : Culture positive at 6 months2 (MGIT) 0.25 (BMD)0.5 (MGIT)138_139insGG1226AXDR: Culture positive at 6 months2 (MGIT) 0.5 (BMD)2 (MGIT)141_142insCG1226A2 XDR isolates: Culture positive at 6 months4 (MGIT) 0.25--0.5 (BMD)0.5--1 (MGIT)T200GG1226AXDR: Culture positive at 6 months4 (MGIT) 0.5 (BMD)2 (MGIT)345delGG1226AXDR: Culture positive at 6 months4 (MGIT) 0.5 (BMD)1 (MGIT)-11C\>AWT--Fully susceptible clinical isolate0.016--[@bib22]D5GWTFully susceptible clinical isolate0.016M23VWTSTR resistant clinical isolate0.063D47fsWTXDR clinical isolate0.5E55DWTFully susceptible clinical isolate0.063G87RWTFully susceptible clinical isolate0.063R96QWTINH resistant0.25L117RWTFully susceptible clinical isolate0.016WT-53G\>AFully susceptible clinical isolate0.125WT-72T\>CRIF and INH resistant clinical isolate8WT-138T\>C3 RIF and INH resistant clinical isolates0.031WT183G\>AFully susceptible clinical isolate0.063WTI66VFully susceptible clinical isolate0.125[^2]Table 3Catalog of previously published mutations from linezolid-resistant in vitro mutants.Table 3**MutationApproachNoteMIC value (µg/ml)Refs.*****rrl****rplC***--T460CSerial passageIsoniazid-resistant strain\>8[@bib1]T460CKanamycin-resistant strain8T460CPyrazinamide-resistant strain\>8T460CRifampicin-resistant strain8--T460CSpontaneousFully susceptible strain\>8G2270C--Pyrazinamide-resistant strain (13 mutants derived)4A2810C--4--T460C8 to \>8G2061T--Spontaneous4 isolates32[@bib23], [@bib24]G2576T--1 isolate16none--5 isolates4-8C2848A--Serial passage17 of 32 had *rrl* mutations, remainder had *rplC*--[@bib25]A2810T--G2270C--G2270T--G2746A----T460C--T460CSpontaneous3 in vitro mutants selected for sequencing16[@bib26]T460C32G2270T--8G2814T--Spontaneous4 isolates25--50[@bib27]--T460C12 isolates50G2299T--7 isolates65--156A2689T--1 isolate60G2814T--4 isolates94[^3]Table 4Catalog of previously published mutations from linezolid-resistant clinical isolates.Table 4**MutationNoteMIC value (µg/ml)Refs.*****rrl****rplC***WT--No mutations in *rplD*, *rplV*, *whiB7*, *rrl*, *erm-*378 (3 strains)[@bib23]WT4 (1 strain)--T460C2 resistant, 3 acquired resistance during treatment4--16[@bib24]G2447T--acquired resistance during treatment16--T460C--2[@bib28]--T460C0.5--T460C4G2576T--4G2576T--4--T460C8 isolates--[@bib19]G2814T--1 isolateC1921T--1 isolateG2294A--1 isolate acquired resistance during treatmentG2576T--1 MDR-TB isolate4[@bib13]A2572C----T460C2 XDR-TB isolates4--16[@bib12][^4]Table 5Mutation frequencies and selection concentrations for bedaquiline-, clofazimine- and linezolid-resistant spontaneous mutants from previously published studies.Table 5**DrugConc (µg/ml)StrainMutation frequencyRefs.**Bedaquiline0.12Fully susceptible *M. tuberculosis*5 × 10^--7^[@bib8]0.12*M. smegmatis*2 × 10^--8^0.24Fully susceptible *M. tuberculosis*5 × 10^--8^0.24*M. smegmatis*1 × 10^--8^0.03-0.05Fully susceptible *M. tuberculosis*1 × 10^--8^[@bib11]Clinical *M. tuberculosis*5 × 10^--8^Clinical *M. tuberculosis*1 × 10^--8^Clinical *M. tuberculosis*1 × 10^--8^0.015-0.5Clinical strain *M. fortuitum*1.5 × 10^--8^0.25-8Clinical strain *M. abscessus*1.5 × 10^--8^1Fully susceptible *M. tuberculosis*6 × 10^--9^[@bib1]Pyrazinamide-resistant *M. tuberculosis*4 × 10^−7^Clofazimine0.25Fully susceptible *M. tuberculosis*5 × 10^−6^[@bib10]1Fully susceptible *M. tuberculosis*5 × 10^−5^[@bib1]Pyrazinamide-resistant *M. tuberculosis*7 × 10^−7^Linezolid--Fully susceptible *M. tuberculosis*2 × 10^−8^[@bib23]--Fully susceptible *M. tuberculosis*5 × 10^−9^2Fully susceptible *M. tuberculosis*1 × 10^−8^[@bib1]Pyrazinamide-resistant *M. tuberculosis*1 × 10^−7^[^5]

2. Experimental design, materials and methods {#s0010}
=============================================

A catalog was compiled of mutations observed for in vitro, in vivo and clinical M. tuberculosis strains resistant to bedaquiline, clofazimine and linezolid as reported in studies that were identified through a comprehensive literature search. This was done by searching for combinations of each drug (or drug class) together with terms like "resistant", "resistance", "mutant", "mutations" as well as "*Mycobacterium tuberculosis*". Related and citing articles were also reviewed. The articles were then analyzed on the basis of the approach used and the mutations documented. Mutations were delineated as arising from either in vivo or clinical and in vitro.
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[^1]: Mutations described in *rv0678*, *atpE* and *rv2535c* genes. A dash (--) is used to indicate where no data is available. WT-wild type, no variants detected. BDQ-Bedaquiline. CFZ-Clofazimine.

[^2]: Mutations described in *rv0678*, *atpE* and *rv1979c* genes. A dash (--) is used to indicate where no data was available. WT-wild type, no variants detected. MGIT- MGIT960 platform used to determine MIC. BMD- Broth Micro Dilution method used to determine MIC. BDQ-Bedaquiline. CFZ-Clofazimine.

[^3]: Mutations described in *rrl* and *rplC* genes. A dash (--) is used to indicate where data was not available.

[^4]: Mutations described in *rrl* and *rplC* genes. A dash (--) is used to indicate where data was not available. WT- wild type, no variants detected.

[^5]: A dash (--) is used to indicate where data was not available.
